Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by topseekeron Jul 21, 2020 8:17am
211 Views
Post# 31294742

Today's NR

Today's NRHi All,

 Enjoy today's read. Upwards and onwards we go.

 Sincerely,

 Topseeker

 020-07-21 08:00 ET - News Release

 

VANCOUVER, British Columbia, July 21, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research study (the “Study”) from UT Dallas’ Center for Advanced Pain Studies, that identified Ifenprodil as one of a number of possible drug candidates for the treatment of COVID -19. The Study was recently published online on June 1, 2020 in Brain, Behaviour, and Immunity.

The Study identified interactions between the immune system and nerves in the lungs that can cause rapid deterioration in COVID-19 patients. The authors looked at the relative gene abundance in the lungs of COVID-19 patients compared to the lungs of healthy controls. In addition to genes that might be expected to be upregulated, the levels of the gene that expressed the NMDA GluN2B receptor in immune cells were also greatly increased.

In an article written by Stephen Fontenot from The University of Texas at Dallas, Dr. Theodore Price, one of the co-authors of the study, suggested that interrupting the interaction between the NMDA receptor and glutamate, one of the neurotransmitters that NMDA receptors respond to, could lessen the damage caused by the infection.

Ifenprodil is an NMDA receptor antagonist specifically targeting the GluN2B subunit, preventing glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

The Company believes that Ifenprodil may reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients. 

In a recent conversation with the Company, Dr. Theodore Price said, “We were really taken aback at the upregulation of NMDA receptors in severe COVID-19 patients. We were even more surprised, when we noted that it was an immune based signal and not neuronal. Based on our findings, we think there is significant opportunity in disrupting NMDA receptor signalling in the lung for reversing pathology in COVID.”

“This study provides significant additional data to what we have already identified, suggesting that Ifenprodil may be an effective treatment for COVID-19,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Article link:https://www.utdallas.edu/news/healthmedicine/nerve-cells-lungs-covid-19-2020/

Research study link: https://linkinghub.elsevier.com/retrieve/pii/S088915912030670X

Bullboard Posts